Dallas, Texas 07/16/2013 (Financialstrend) – Recently, Global Market Direct published the “XOMA Corporation – Product Pipeline Review – 2013” pharmaceuticals report, which provides all the data of XOMA Corp (NASDAQ:XOMA), particularly on the development and research activities of the company. It also focuses on features of discontinued and dormant projects, complete with latest update and current developments in pipeline products. This report is published with the data and information collected from XOMA Corporation’s corporate website, investor presentations, proprietary databases of Global Markets Direct, SEC filings, and XOMA Corporation and industry-specific third party’s featured press releases. The report contains an overview of Xoma Corporation which is briefly stated and includes key information, business description, its subsidiaries, locations, facts, review of current pipeline of the company in various stages of development.
Socks of XOMA Corp (NASDAQ:XOMA) were ranked at the Best 5 in the pharmaceuticals industry along with Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) and InterMune, Inc. (NASDAQ:ITMN). The development partner of XOMA Corporation, SERVIER, launched its Proof-of-Concept (POC) clinical program independently. This program evaluates the efficacy and safety of gevokizumab, a potent modulator. In November 2011 Xoma also launched a similar program.
Intraday range was from a low price of $4.56 to a high price of $5.10. The share price of XOMA Corp (NASDAQ: XOMA) closed for the day at $4.74, recording an increase of 4.64%. The price range of XOMA Corp for the past 52 weeks was from $2.37 to $5.10. The stock opened at the price of $4.70 on Monday with a market capitalization of $392.91 million and 82.89 million outstanding shares. With an institutional ownership of 70%, the trading volume for the day of XOMA Corp was 2.60 million and the average trading volume was 777,489.00 shares.